-
Je něco špatně v tomto záznamu ?
Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study
K. Holl, AM. Nowakowski, N. Powell, WG. McCluggage, EC. Pirog, S. Collas De Souza, WA. Tjalma, M. Rosenlund, A. Fiander, M. Castro Sánchez, V. Damaskou, EA. Joura, B. Kirschner, R. Koiss, J. O'Leary, W. Quint, O. Reich, A. Torné, M. Wells, L....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26096203
DOI
10.1002/ijc.29651
Knihovny.cz E-zdroje
- MeSH
- adenoskvamózní karcinom epidemiologie virologie MeSH
- dospělí MeSH
- dysplazie děložního hrdla epidemiologie virologie MeSH
- infekce papilomavirem epidemiologie virologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidský papilomavirus 16 genetika MeSH
- mladý dospělý MeSH
- nádory děložního čípku epidemiologie virologie MeSH
- prevalence MeSH
- průřezové studie MeSH
- retrospektivní studie MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
Cervical glandular neoplasias (CGN) present a challenge for cervical cancer prevention due to their complex histopathology and difficulties in detecting preinvasive stages with current screening practices. Reports of human papillomavirus (HPV) prevalence and type-distribution in CGN vary, providing uncertain evidence to support prophylactic vaccination and HPV screening. This study [108288/108290] assessed HPV prevalence and type-distribution in women diagnosed with cervical adenocarcinoma in situ (AIS, N = 49), adenosquamous carcinoma (ASC, N = 104), and various adenocarcinoma subtypes (ADC, N = 461) from 17 European countries, using centralised pathology review and sensitive HPV testing. The highest HPV-positivity rates were observed in AIS (93.9%), ASC (85.6%), and usual-type ADC (90.4%), with much lower rates in rarer ADC subtypes (clear-cell: 27.6%; serous: 30.4%; endometrioid: 12.9%; gastric-type: 0%). The most common HPV types were restricted to HPV16/18/45, accounting for 98.3% of all HPV-positive ADC. There were variations in HPV prevalence and ADC type-distribution by country. Age at diagnosis differed by ADC subtype, with usual-type diagnosed in younger women (median: 43 years) compared to rarer subtypes (medians between 57 and 66 years). Moreover, HPV-positive ADC cases were younger than HPV-negative ADC. The six years difference in median age for women with AIS compared to those with usual-type ADC suggests that cytological screening for AIS may be suboptimal. Since the great majority of CGN are HPV16/18/45-positive, the incorporation of prophylactic vaccination and HPV testing in cervical cancer screening are important prevention strategies. Our results suggest that special attention should be given to certain rarer ADC subtypes as most appear to be unrelated to HPV.
Clinics Biostatistics Paris France
DDL Diagnostic Laboratory Rijswijk The Netherlands
Department of Anatomical Pathology General Hospital of Patras Achaia Greece
Department of Obstetrics and Gynaecology Hvidovre University Hospital Hvidovre Copenhagen Denmark
Department of Obstetrics and Gynecologic Oncology St Stephan Hospital Budapest Hungary
Department of Obstetrics and Gynecology Medical University of Graz Graz Austria
Department of Oncology University of Sheffield Medical School Sheffield England United Kingdom
Department of Pathology Belfast Health and Social Care Trust Belfast Northern Ireland United Kingdom
Epidemiology Department GlaxoSmithKline Vaccines Wavre Belgium
Global Health Economics GSK Vaccines Wavre Belgium
Institute of Oncology of RAMS Siberian Branch Tomsk Russia
Obstetrics and Gynaecology Department University Hospital Puerto De Hierro Majadahonda Madrid Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010079
- 003
- CZ-PrNML
- 005
- 20160414105646.0
- 007
- ta
- 008
- 160408s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ijc.29651 $2 doi
- 024 7_
- $a 10.1002/ijc.29651 $2 doi
- 035 __
- $a (PubMed)26096203
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Holl, Katsiaryna $u Global Health Economics, GSK Vaccines, Wavre, Belgium.
- 245 10
- $a Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study / $c K. Holl, AM. Nowakowski, N. Powell, WG. McCluggage, EC. Pirog, S. Collas De Souza, WA. Tjalma, M. Rosenlund, A. Fiander, M. Castro Sánchez, V. Damaskou, EA. Joura, B. Kirschner, R. Koiss, J. O'Leary, W. Quint, O. Reich, A. Torné, M. Wells, L. Rob, L. Kolomiets, A. Molijn, A. Savicheva, E. Shipitsyna, D. Rosillon, D. Jenkins,
- 520 9_
- $a Cervical glandular neoplasias (CGN) present a challenge for cervical cancer prevention due to their complex histopathology and difficulties in detecting preinvasive stages with current screening practices. Reports of human papillomavirus (HPV) prevalence and type-distribution in CGN vary, providing uncertain evidence to support prophylactic vaccination and HPV screening. This study [108288/108290] assessed HPV prevalence and type-distribution in women diagnosed with cervical adenocarcinoma in situ (AIS, N = 49), adenosquamous carcinoma (ASC, N = 104), and various adenocarcinoma subtypes (ADC, N = 461) from 17 European countries, using centralised pathology review and sensitive HPV testing. The highest HPV-positivity rates were observed in AIS (93.9%), ASC (85.6%), and usual-type ADC (90.4%), with much lower rates in rarer ADC subtypes (clear-cell: 27.6%; serous: 30.4%; endometrioid: 12.9%; gastric-type: 0%). The most common HPV types were restricted to HPV16/18/45, accounting for 98.3% of all HPV-positive ADC. There were variations in HPV prevalence and ADC type-distribution by country. Age at diagnosis differed by ADC subtype, with usual-type diagnosed in younger women (median: 43 years) compared to rarer subtypes (medians between 57 and 66 years). Moreover, HPV-positive ADC cases were younger than HPV-negative ADC. The six years difference in median age for women with AIS compared to those with usual-type ADC suggests that cytological screening for AIS may be suboptimal. Since the great majority of CGN are HPV16/18/45-positive, the incorporation of prophylactic vaccination and HPV testing in cervical cancer screening are important prevention strategies. Our results suggest that special attention should be given to certain rarer ADC subtypes as most appear to be unrelated to HPV.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a adenoskvamózní karcinom $x epidemiologie $x virologie $7 D018196
- 650 _2
- $a dysplazie děložního hrdla $x epidemiologie $x virologie $7 D002578
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidský papilomavirus 16 $x genetika $7 D052162
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a infekce papilomavirem $x epidemiologie $x virologie $7 D030361
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a nádory děložního čípku $x epidemiologie $x virologie $7 D002583
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Nowakowski, Andrzej M $u First Department of Oncologic Gynaecology and Gynaecology, Medical University of Lublin, Poland. Department of Gynaecology and Oncologic Gynaecology, Military Institute of Medicine, Warsaw, Poland.
- 700 1_
- $a Powell, Ned $u Institute of Cancer and Genetics, HPV Research Group, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom.
- 700 1_
- $a McCluggage, W Glenn $u Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom.
- 700 1_
- $a Pirog, Edyta C $u Department of Pathology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY.
- 700 1_
- $a Collas De Souza, Sabrina $u 4Clinics, Biostatistics, Paris, France (at the time of study).
- 700 1_
- $a Tjalma, Wiebren A $u Multidisciplinary Breast Clinic-Gynecological Oncology Unit, Department of Obstetrics and Gynecology, Antwerp University Hospital, University of Antwerp, Antwerpen, Belgium.
- 700 1_
- $a Rosenlund, Mats $u IMS Health, Stockholm, Sweden. Center for Pharmacoepidemiology, Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Solna, Sweden.
- 700 1_
- $a Fiander, Alison $u Institute of Cancer and Genetics, HPV Research Group, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom.
- 700 1_
- $a Castro Sánchez, Maria $u Obstetrics and Gynaecology Department, University Hospital Puerto De Hierro Majadahonda, Madrid, Spain.
- 700 1_
- $a Damaskou, Vasileia $u Department of Anatomical Pathology, General Hospital of Patras, Achaia, Greece.
- 700 1_
- $a Joura, Elmar A $u Comprehensive Cancer Center, Department of Gynecology and Obstetrics, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Kirschner, Benny $u Department of Obstetrics and Gynaecology, Hvidovre University Hospital, Hvidovre, Copenhagen, Denmark.
- 700 1_
- $a Koiss, Robert $u Department of Obstetrics and Gynecologic Oncology, St. Stephan Hospital, Budapest, Hungary.
- 700 1_
- $a O'Leary, John $u CERVIVA Research Consortium, Funded by the Health Research Board Ireland, Based at the Department of Pathology, The Coombe Women and Infants University Hospital and Trinity College, Dublin, Ireland.
- 700 1_
- $a Quint, Wim $u DDL Diagnostic Laboratory, Rijswijk, The Netherlands.
- 700 1_
- $a Reich, Olaf $u Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria.
- 700 1_
- $a Torné, Aureli $u Hospital Clinic, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain.
- 700 1_
- $a Wells, Michael $u Department of Oncology, University of Sheffield Medical School, Sheffield, England, United Kingdom.
- 700 1_
- $a Rob, Lukas $u University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Kolomiets, Larisa $u Institute of Oncology of RAMS Siberian Branch, Tomsk, Russia.
- 700 1_
- $a Molijn, Anco $u DDL Diagnostic Laboratory, Rijswijk, The Netherlands.
- 700 1_
- $a Savicheva, Alevtina $u Laboratory of Microbiology, DO Ott Research Institute of Obstetrics and Gynaecology, St. Petersburg, Russia.
- 700 1_
- $a Shipitsyna, Elena $u Laboratory of Microbiology, DO Ott Research Institute of Obstetrics and Gynaecology, St. Petersburg, Russia.
- 700 1_
- $a Rosillon, Dominique $u Epidemiology Department, GlaxoSmithKline Vaccines, Wavre, Belgium.
- 700 1_
- $a Jenkins, David $u DDL Diagnostic Laboratory, Rijswijk, The Netherlands.
- 773 0_
- $w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 137, č. 12 (2015), s. 2858-68
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26096203 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160414105730 $b ABA008
- 999 __
- $a ok $b bmc $g 1113508 $s 934447
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 137 $c 12 $d 2858-68 $e 20150714 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
- LZP __
- $a Pubmed-20160408
